Clinical trial NCT04890574: CellMist™ Autologous Cells to Treat Deep Second-Degree Burns
Official title: An Open Label Pilot Study to Evaluate the CellMist™ System in the Treatment of Deep Second Degree (IIoB) Burn Injuries With Autologous Skin Cells
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Burns
Burns Second Degree
Burns Deep Second Degree
Keywords: Cell Therapy
Burn Injury
Lead sponsor: RenovaCare, Inc
Sponsor class: INDUSTRY
First posted: 2021-05-18
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: This is a prospective, single arm, open label non-randomized safety and device feasibility study.
Primary purpose: TREATMENT

Brief summary: The overall purpose of this study is to evaluate the safety of the CellMist™ System in the treatment of deep second degree burns (II°B) in a prospective, multicenter, feasibility pilot study.

Detailed description: Patients between the ages of 18 and 65 years of age inclusive with a ≤ 30% Total Body Surface Area (TBSA) that requires surgical or enzymatic debridement and split thickness skin grafting (STSG) on any body surface excluding the face, joints, perineum and hands will be considered for participation in this study. CellMist™ solution (autologous epidermal and dermal cells) will be administered, via the System Skin Gun™, will be evenly distributed to aid in burn healing. Healing, pain and treatment-related adverse events will be evaluated at follow-up visits. Data concerning safety of the CellMist™ System will be collected. Safety will be evaluated in terms of treatment and serious related adverse events.

Each subject will participate in up to 9 total visits (screening, treatment and 7 follow-up study visits) over a period of 52 weeks. Up to 14 subjects will be enrolled and treated within this at up to 4 institutions.

Eligibility criteria: Inclusion Criteria:

1. Is between 18 and 65 years of age inclusive;
2. Has at least one discrete deep second degree (II°B) thermal burn injury (≤ 30% Total Body Surface Area (TBSA)) that requires surgical or enzymatic debridement and split thickness skin grafting (STSF) on any body surface excluding the face, joints, perineum and hands;
3. Agrees to abstain from any other surgical treatment of the wound(s) for the duration of the study unless determined by the Principal Investigator to be medically necessary;
4. Treatment with CellMist™ occurs with 7 days of burn injury;
5. Demonstrates (as determined by the Principal Investigator) the ability and willingness to follow the requirements of the protocol;
6. Understand the full nature and purpose of the study and provides voluntary written informed consent -

Exclusion Criteria:

1. Is pregnant or does not agree to use acceptable contraception methods for the duration of their participation in the clinical trial (latter applies to women and men of child bearing potential);
2. Is breast feeding;
3. Has a pre-existing local and/or systemic bacterial infection that requires antibiotic treatment for more than 2 days prior to study treatment;
4. Demonstrates an anesthesia risk that (as determined by the Principal Investigator) prohibits treatment
5. Body Mass Index (BMI) ≥ 39;
6. The burn(s) at the target treatment area(s) results from chemical, electrical or radiation exposure;
7. Has full thickness (III°) burns TBSA ≥ 20%
8. Has comorbidities and/or medications and/or health status that (as determined by the Principal Investigator) could result in poor cell isolation and/or poor wound healing (e.g., uncontrolled and/or significant diabetes (≥8% HbA1c by medical record), peripheral vascular disease, active malignancy or treatment (other than surgery) of malignancy within the past 3 months, autoimmune disease, renal failure (glomerular filtration rate \<60mL/minute) and/or systemic steroid usage);
9. Known hypersensitivities to trypsin, collagenase, or GentLyase (dispase);
10. Has a medical condition that would make life expectancy \< 12 months;
11. Is currently participating in another prospective investigational clinical trial;
12. Does not agree to abstain from enrolling in any other study for the duration of this study;
13. Gram staining of SkinGun™ cell suspension output shows excessive microbial bioburden (≥ 200 microbial particles/field)

Primary outcomes:
measure: All Adverse Events
timeFrame: We will be evaluating all adverse events reported for the period from enrollment through the final visit which will be 12 months
measure: Secondary Surgical Interventions
timeFrame: The evaluation will include all reported secondary surgical interventions for the period from enrollment and up to 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Washington
country: United States
facility: Washington MedStar Hospital
state: District of Columbia
Study officials:
References: